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Introduction: Tyrosine kinase inhibitors are widely prescribed in thoracic oncology and have excellent responses as
a first-line treatment for locally advanced or metastatic lung cancer with epidermal growth factor receptor mutations.
The side effects of tyrosine kinase inhibitors are mostly gastrointestinal and dermatological, and are usually resolved
after symptomatic treatment. However, new complications have now arisen due to increased use of these drugs. Here
we report a side effect of erlotinib that has not been described previously: that is, metastatic lung tumor nodules were
transformed into cysts, which ruptured the pleura and were responsible for bilateral life-threatening pneumothorax.
Case presentation: We report the case of a 35-year-old Caucasian woman with metastatic adenocarcinoma and a
deletion in epidermal growth factor receptor exon 19 (del E746-A750). She was treated with erlotinib for metastatic
lung adenocarcinoma.
Treatment with erlotinib resulted in the replacement of pulmonary tumor nodules with air-containing cysts. These
cysts ruptured in the pleura causing a life-threatening bilateral pneumothorax.
To the best of our knowledge, this tumor–cystic response after erlotinib therapy has not been previously described.
Conclusions: Tyrosine kinase inhibitors are widely prescribed in thoracic oncology, and managing toxicities must be
optimal in order to improve adherence. Transformation of pulmonary nodules into cysts must be known and
clinicians should be aware of this potential complication, which can lead to life-threatening pneumothorax.
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Tyrosine kinase inhibitorsIntroduction
Targeted therapies in thoracic oncology are starting to
compete with ‘classic’ chemotherapies due to their better
clinical tolerance and easier mode of administration.
However, we are now faced with a new complication be-
cause of their increased usage. Tyrosine kinase inhibitors
(TKIs) are now widely prescribed in thoracic oncology:
thus, managing any toxicity should be optimal to improve
adherence. Here we report a case in which erlotinib caused
transformation of pulmonary nodules into cysts; this has
not been described previously in the literature.
Case presentation
A 35-year-old Caucasian woman and former cigarette
smoker presented with dyspnea and neck pain. A* Correspondence: lsakhri@chu-grenoble.fr
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unless otherwise stated.computed tomography (CT) scan revealed bilateral round
opacities in both lungs (Figure 1A, C), hepatic metastases,
osteolysis of her second cervical vertebra (C2) (Figure 2A),
and two cerebral metastases. A percutaneous biopsy of the
hepatic metastasis showed lung adenocarcinoma with a
deletion in the epidermal growth factor receptor exon 19
(del E746-A750).
Treatment with erlotinib was started. After 2 months
she was hospitalized in our intensive care unit for an
acute respiratory distress syndrome, secondary to a bilat-
eral and spontaneous pneumothorax, which required
placement of a chest tube. A thoracic CT scan revealed
the replacement of diffuse parenchymatous nodules by
cystic lesions (Figure 1B, D). Because of prolonged air
leakage but also a good response to oncological treat-
ment, a two-stage thoracoscopic bilateral talc poudrage
was performed. Her postoperative course was uneventful
and the drains were removed at 3 weeks after surgery.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Thoracic computed tomography scan. (A) (C) Initial thoracic computed tomography scan showing multiple pulmonary metastases.
(B) (D) Thoracic computed tomography scan after 2 months of treatment with erlotinib, showing a partial thoracic response with the appearance
of pulmonary cysts and a partially drained bilateral pneumothorax.
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second-line treatment of cisplatin, pemetrexed, and bev-
acizumab followed by a maintenance therapy of bevaci-
zumab, was given. After 6 months of chemotherapy, the
tumor had progressed and erlotinib was reintroduced.
This therapy was associated with a cerebral infarction in
the context of paraneoplastic syndrome. The patient
died 18 months later from disease progression.
Discussion
In this patient, erlotinib gave an excellent initial response;
there was complete disappearance of the cerebral metas-
tases, and the osteocondensation of the C2 vertebraeA
Figure 2 Computed tomography scan of the neck. (A) revealing C2 ost
indicated by the arrow) in the location of the initial lysis of the C2 vertebra(Figure 2B). However, lysis of the subpleural metastases
(Figure 1B, C) could explain the occurrence of the cystic
lesions and pneumothorax.
We have recently reported a case in which there was
transformation of pulmonary nodules into pulmonary
cysts in a 40-year-old woman who was a non-cigarette
smoker with multi-metastatic pulmonary adenocarcinoma,
an EML4-ALK gene rearrangement, and who was success-
fully treated with crizotinib [1].
The phenomenon of cyst formation is caused by par-
enchymal necrosis as a result of targeted therapy, but
which also increases the risk of a pneumothorax. Tumor
necrosis has previously been described in connectionB
eolysis as indicated by the arrow. (B) showing osteocondensation (as
e after 2 months of treatment with erlotinib.
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germinal tumors, lymphomas, and sarcomas [2,3], with a
1% risk of a pneumothorax occurring within 2 to 7 days
following the start of chemotherapy [4].
Transformation of tumor lesions into cysts is also a diffi-
culty in Response Evaluation Criteria in Solid Tumours
assessments. The solid tumors initially retain the same
diameter as the newly formed cysts.
TKIs are prescribed as a first-line therapy in the con-
text of sensitive mutations, and produce a response rate
of 50 to 90% and progression-free survival times of 9.7
to 13.1 months; this is compared to 4.6 to 5.2 months in
patients treated with a platinum-based chemotherapy [5].
Here we report the unusual response of the lung after
erlotinib therapy, in which the lung nodules were trans-
formed into cysts via a mechanism that was probably
associated with necrosis.
Conclusions
The association between lysis of a lung tumor and its re-
placement by a cyst seemed to be caused by erlotinib
treatment: thus, this should be borne in mind, as the rup-
ture of a cyst in the pleura can result in a life-threatening
pneumothorax.
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